Transcript Open Science Summit 2011 10 21 transparency life sciences.ppt

Crowdsourcing Clinical Drug
Development
in a transparent model
Tomasz Sablinski M.D., Ph.D.
Founder, Transparency Life Sciences
Head of Development, Celtic Therapeutics
Open Science Summit
Mountain View, CA
Oct 23, 2011
Perspectives
- clinical investigator
- basic researcher
- biotech consultant
- CRO
- big pharma
- investor
- entrepreneur
the drug development industry is
facing extinction
psychotherapy is not an answer
intensive care is the only hope
“open innovation”
the abuse of terminology
Obvious fields:
- pre-competitive space
- sharing data on:
placebo response
failed clinical studies
Obstacles to crowdsourcing and
transparency in pharma
- legal
- IP
- arrogance of experts
- fear for loosing jobs
- secretive culture
- antiquated computer sciences
- development / marketing confluence
Drug Development
Attacking the sources
of waste
Sources of Waste
partial list………
+
Pharma Company
Infrastructure
+
+
+
Multiple Patient Visits
to Expensive Sites
High-Cost
Patient Recruitment
Insular Approach to
Protocol Design
=
20th Century Data
Capture & Analyses
8
New model:
a platform for collecting key information,
analyzing it, and building knowledge in a
transparent, complete, easy to understand format
to enable multiple parties to move a project ahead
in a virtual global environment
secrecy = legacy
transparency = currency
Transparency Life Sciences
is a Drug Development Company
We acquire IP and pharmaceutical assets
from academia, biotech, and pharma, and
add significant value by conducting clinical
studies via open-source methods, and by
executing with unmatched productivity.
11
Passionate About Changing the World
of Drug Development
Founders
Tomasz Sablinski, MD, Ph.D. – Harvard, Novartis, Celtic Rx
Marc Foster – FoldRx, Schrodinger, multiple exits in high tech
Gareth Hicks, Ph.D. – Cambridge, GSK, Novartis, Tioga
Lawrence Steinman, MD – Professor - Stanford, multiple biotechs
Advisors
Karim Lakhani – Harvard Business School
Bernard Munos – Former strategist, Eli Lilly
John L. Brown – Former President, Health Properties, Time-Warner
Scott Becker – Co-Founder, Invite Media (acquired by Google)
12
Three major enablers:
technology
social changes / culture
crisis
TLS Approach
1.
Crowd-Sourcing – an approach to protocol
design and data analysis, allowing for input from
all available stakeholders
“10,000 minds are better than 10”
2. Data & Technology Platform – web-based
platform integrating multiple real-time
data inputs via telemedicine
Enhance trial cost-efficiency, safety, data
3. Transparency – Plans, data, analyses are shared
openly, in real time
Builds trust in TLS, provides best analyses
14
How Will it Work in Practice?
High-Level View
Trial Step
Protocol
Design
Patient
Recruitment
Study
Execution
Data
Collection
Analysis
Telemedicine
Secure,
Open
Vendors
More
Crowd
Input
Key Leverage Point
CrowdSourcing
Online
Groups
15
Why do people “go to” work?
because of the context
($$ is the major incentive)
Why do people contribute?
because of their passion for the
content
($$ is NOT the major incentive!)
For TLS partnerships are essential
Patients web groups
Disease foundations
Telemedicine companies
Genetic testing enterprises
Bioinformatics companies
Focus: Clinical studies
Welcome to our project collaborative space !